Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
10.3760/cma.j.issn.0253-3766.2019.12.012
- VernacularTitle: 晚期非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂临床研发和审评考虑
- Author:
Ming ZHOU
1
;
Dongmei CHEN
1
;
Lin XIA
1
;
Yuanyuan SONG
1
;
Yuankai SHI
2
;
Zhimin YANG
1
Author Information
1. Center for Drug Evaluation, China National Medical Products Administration, Beijing 100022, China
2. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Neoplasms, non-small cell lung;
Epidermal growth factor receptor tyrosine kinase inhibitor;
New drug, clinical research and development;
Technique review
- From:
Chinese Journal of Oncology
2019;41(12):949-952
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most frequently diagnosed cancer and the most common cause of cancer mortality in China. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancers. The mutation rate of epidermal growth factor receptor (EGFR) gene is relatively high, accounts for 32%~38% of all NSCLC. During the last decade, the application of EGFR specific tyrosine kinase inhibitors (TKI) significantly improved prognosis of NSCLC patients with sensitive EGFR mutations. Thus, the research and development of third generation EGFR-TKI have entered the period of rapid development. The fourth generation EGFR-TKI which targeting EGFR C797S has even begun clinical development in China. This review will discuss the clinical research and drug review of EGFR-TKI from the perspective of drug review.
